A detailed history of Royal Bank Of Canada transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Royal Bank Of Canada holds 4,130 shares of LGND stock, worth $438,936. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,130
Previous 3,539 16.7%
Holding current value
$438,936
Previous $298,000 38.59%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$82.7 - $110.11 $48,875 - $65,075
591 Added 16.7%
4,130 $413,000
Q2 2024

Aug 14, 2024

BUY
$68.53 - $87.91 $85,936 - $110,239
1,254 Added 54.88%
3,539 $298,000
Q1 2024

Nov 05, 2024

SELL
$68.64 - $89.2 $86,074 - $111,856
-1,254 Reduced 35.43%
2,285 $167,000
Q1 2024

May 15, 2024

SELL
$68.64 - $89.2 $322,813 - $419,507
-4,703 Reduced 67.3%
2,285 $167,000
Q4 2023

Feb 14, 2024

BUY
$49.57 - $72.63 $84,814 - $124,269
1,711 Added 32.42%
6,988 $499,000
Q3 2023

Nov 14, 2023

BUY
$58.86 - $72.67 $17,716 - $21,873
301 Added 6.05%
5,277 $316,000
Q2 2023

Aug 14, 2023

BUY
$69.53 - $79.33 $140,102 - $159,849
2,015 Added 68.05%
4,976 $358,000
Q1 2023

May 15, 2023

SELL
$65.67 - $77.08 $131,996 - $154,930
-2,010 Reduced 40.43%
2,961 $217,000
Q4 2022

Feb 14, 2023

BUY
$61.72 - $96.74 $176,334 - $276,386
2,857 Added 135.15%
4,971 $332,000
Q3 2022

Nov 14, 2022

BUY
$0.01 - $107.56 $2 - $25,061
233 Added 12.39%
2,114 $183,000
Q2 2022

Aug 15, 2022

SELL
$74.52 - $117.06 $62,298 - $97,862
-836 Reduced 30.77%
1,881 $168,000
Q1 2022

May 16, 2022

SELL
$94.99 - $151.56 $244,314 - $389,812
-2,572 Reduced 48.63%
2,717 $306,000
Q4 2021

Feb 14, 2022

BUY
$127.69 - $165.85 $146,077 - $189,732
1,144 Added 27.6%
5,289 $817,000
Q3 2021

Nov 15, 2021

SELL
$102.33 - $144.73 $1.84 Million - $2.61 Million
-18,001 Reduced 81.28%
4,145 $578,000
Q2 2021

Aug 16, 2021

BUY
$113.03 - $155.64 $2.5 Million - $3.45 Million
22,146 New
22,146 $2.91 Million

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.79B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.